Telehealth companies jump onto peptides amid expected FDA ref relief.

{
  "signal_id": "c97c2b85-0c5a-4475-b7b0-23c34ab5c698",
  "signal_type": "news",
  "signal_subtype": "invests_into_assets",
  "detected_at": "2026-04-02T00:00:00+00:00",
  "company": {
    "name": "Noom",
    "domain": "noom.com"
  },
  "data": {
    "url": "https://insidehealthpolicy.com/daily-news/telehealth-companies-jump-peptides-amid-expected-fda-ref-relief",
    "title": "Telehealth companies jump onto peptides amid expected FDA ref relief.",
    "assets": "peptide-producing facilities",
    "excerpt": "Telehealth companies jump onto peptides amid expected FDA ref relief.\n\nTelehealth giants Noom and Hims & Hers recently acquired peptide-producing facilities, coming as FDA reportedly plans to allow compounding pharmacies to produce some injectable peptides that previously were banned due to potential safety risks.\n\nNot a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, medicaid policy, FDA news and much more.\n\nNEWSLETTERS\n\nInside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.\n\nSITE LICENSES\n\nEconomical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or h***@iwpnews.com.\n\nSTAY CONNECTED\n\n(C) 2002-2026. Inside Washington Publishers | Contact Us",
    "summary": "Noom Inc. invested into assets: peptide-producing facilities on Apr 1st '26.",
    "category": "invests_into_assets",
    "found_at": "2026-04-02T00:00:00Z",
    "planning": false,
    "image_url": "https://insidehealthpolicy.com/sites/insidehealthpolicy.com/files/health_logo.jpg",
    "confidence": 0.4089,
    "published_at": "2026-04-02T00:00:00Z",
    "effective_date": "2026-04-01",
    "article_sentence": "Telehealth giants Noom and Hims & Hers recently acquired peptide-producing facilities, coming as FDA reportedly plans to allow compounding pharmacies to produce some injectable peptides that previously were banned due to potential safety risks."
  }
}

curl https://signals.autobound.ai/v1/signals/c97c2b85-0c5a-4475-b7b0-23c34ab5c698 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"noom.com","limit":20}'